Hawryluk P. Kent 4
4 · MBX Biosciences, Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
MBX Biosciences (MBX) CEO P. Kent Hawryluk Receives Equity Awards
What Happened
P. Kent Hawryluk, President & CEO and a director of MBX Biosciences, was granted a total of 199,750 shares of equity compensation on February 2, 2026: 35,250 restricted stock units (RSUs) and a 164,500-share derivative award. Both grants were reported at $0.00 per share (standard for RSU/option awards), so no cash was paid. These are compensation awards (not open-market purchases or sales).
Key Details
- Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (timely filing).
- Grants: 35,250 RSUs (reported as acquisition A) and 164,500 derivative shares (reported as acquisition A). Price: $0.00 per share.
- Vesting: RSUs vest over four years in equal quarterly installments (footnote F1). The 164,500-share derivative vests in 48 equal monthly installments beginning March 2, 2026 (footnote F3).
- Shares held via trust: filing notes shares held by the P. Kent Hawryluk Revocable Trust dated Jan 25, 2011; he disclaims beneficial ownership except for any pecuniary interest (footnote F2).
- Shares owned after the transaction: not specified in the supplied filing details.
Context
RSUs and derivative awards are standard executive compensation and only convert into sellable shares as they vest; they do not indicate an immediate purchase or sale by the insider. The grants were reported promptly (next-business-day filing), and the staged vesting ties future ownership to continued service.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-02+35,250→ 699,506 total - Award
Stock option (right to buy)
[F3]2026-02-02+164,500→ 164,500 totalExercise: $39.07Exp: 2036-02-02→ Common Stock (164,500 underlying)
- 468,277(indirect: By Trust)
Common Stock
[F2]
Footnotes (3)
- [F1]Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date.
- [F2]Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F3]The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date.